Serenno Medical Overview
Serenno Medical is developing a novel method to monitor fluid balance and predict, identify, and avoid common life-threatening complications in intensive care unit (ICU) hospitalizations such as acute kidney injury (AKI). Serenno is using a robust, hands-free, low-cost, and noninvasive device that measures accurate, ongoing urine output. The devices enable contact-free monitoring of hospitalized, quarantined, and home ICU patients. Using the system, medical personnel are alerted to conditions requiring immediate attention, helping to predict and avoid AKI with no need for massive interventions and reducing costs and length of stay.
Cumulative Funding Raised Over Time ($)
Latest News
growth-positive
Elcam Medical invests $1.5 million in Serenno Medical for kidney monitoring device
Elcam Medical, an Israeli healthtech company, will invest $1.5 million in Serenno Medical to manufacture their urine output and intra-abdominal pressure digital monitoring device, Sentinel. The device is designed to detect acute kidney injuries (AKI) and will be used in hospitals to monitor kidney health. Other investors include Alon Medtech Ventures. Sentinel can detect early symptoms of AKI by measuring urine output and can be used for remote monitoring, reducing the risk to hospital staff. Serenno plans to deploy the devices in several US hospitals by the end of 2021.
InvestmentPartners
growth-positive
https://www.jpost.com/HEALTH-SCIENCE/Israeli-tech-firm-develops-life-saving-automatic-kidney-monitoring-device-616628
Serenno Medical, a med-tech company, has developed an automated device for monitoring kidney function and detecting kidney damage in hospitalized patients. The device offers continuous and automated monitoring of urine output, allowing for early detection of acute kidney injury. The company aims to receive FDA clearance this year and plans to launch in the US by the end of the year. Serenno Medical is also focusing on manufacturing the device, securing funding and strategic partnerships, and conducting additional clinical trials. The company was founded in 2017 and is a portfolio company of Alon Medtech Ventures.
CustomersInvestment
growth-positive
Serenno Medical Introduces Novel Device for Continuous Automatic Monitoring of Kidney Function of Hospitalized Patients
Serenno Medical, a developer of medical devices for patient monitoring, has revealed Sentinel™, a device for automatic monitoring and detection of kidney damage in hospitalized patients. The Sentinel device is a continuous urine output monitor that measures urine flow rate and volume in real time. The device aims to promote early detection of kidney injury and provide actionable data. Serenno recently completed its first multicenter clinical trial, showing high reliability and accuracy. The company plans to move forward with manufacturing the device for commercial usage and expects to receive FDA clearance in 2020. Acute Kidney Injury (AKI) affects approximately 19 million patients worldwide every year, and Serennos device has the potential to become the standard-of-care in the OR and ICU.
Customers
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $2.4M |
| Last funding | Undisclosed |
| Stage | A |
| Rounds | 3 |
| Investors | 3 |
Team Members
3
Employees: 1-10
Web & Social Links
| Website | www.serenno-med.com |
| Careers | Careers page |
Locations
Yokne'am Illit, Israel
Photos & Videos
1 item(s)
